Original release date: March 28, 2019
Access to this course expires on: January 24, 2022, at 11:59 PM Pacific Time
The microscopic pattern of liver biopsies for non-neoplastic diseases has changed with increasing emphasis on steatohepatitis, fibrosis regression and drug-induced liver disease. The reasons for these changes (based on consultative cases at several large medical centers) include classification of an hepatic pattern of injury, primary biliary cholangitis, fatty liver disease, autoimmune hepatitis, etiology of cirrhosis and transplant pathology (unpublished data). Among the neoplastic cases, hepatocellular carcinoma, cholangiocarcinoma/metastatic adenocarcinoma and hepatocellular adenoma are the leading areas that cause problems in diagnosis for practicing pathologists. Advances in radiologic techniques facilitate targeting smaller lesions, necessitating judicious use of immunohistochemistry. In the last few years, characteristic molecular changes have been described in a variety of liver tumors and are increasingly being used for diagnosis. Take advantage of this fantastic mentoring opportunity to study liver interactively with experts who can improve your performance and enhance your practice.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
- Formulate pattern diagnosis for hepatitis and biliary diseases, and narrow the differential diagnosis based on clinical features
- Recognize liver infections and common features of liver involvement in systemic diseases
- Obtain appropriate immunohistochemical stains for focal nodular hyperplasia, hepatocellular adenoma and hepatocellular carcinoma
- Distinguish benign and malignant biliary proliferations on biopsies and frozen sections
Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.25. AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 12.25 SAM/Part II credit hours.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Sanjay Kakar, MD, Dhanpat Jain, MD, Laura W. Lamps, MD, Michael Torbenson, MD
The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Rhonda K. Yantiss, MD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
To earn CME and SAM credit, all learners must complete the evaluation. Your certificate will be available to view and print by clicking here.
Buy the entire Liver Pathology: Translating a World of Colors into Clinically Relevant Pathology Reports course and get a great discount!
Not A Member? Click Here